North America Autoimmune Disease Diagnostics Market Size (2024 - 2029)

North America Autoimmune Disease Diagnostics Market Analysis

The North America Autoimmune Disease Diagnostics Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.68 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).

• The rising prevalence of autoimmune diseases and growing public awareness of autoimmune disorders are the primary factors driving the market growth. For instance, study data published by the University of Oxford in May 2023 reported that about one in 10 individuals in the United Kingdom was affected by autoimmune disorders in 2022. These autoimmune conditions include 19 diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. It also stated that 10% of the overall population was affected by these autoimmune diseases, a significant percentage. Hence, the high burden of autoimmune diseases is expected to increase the demand for diagnostics, boosting market growth during the forecast period.
• Moreover, strategic activities such as product launches by major regional market players are expected to boost market growth, enabling patients to have diversified access to various products. For instance, in March 2024, AMPEL BioSolutions launched LuGENE, a pioneering blood test, in the United States. This test is specifically designed to predict flares in systemic lupus erythematosus (SLE) and provide detailed insights into the unique nuances of each patient's condition. This, in turn, facilitates swifter, evidence-driven treatment, which is expected to be in significant demand over the coming years. Hence, the new product launches will likely drive market growth during the forecast period.
• Therefore, the factors above, such as the high prevalence of autoimmune disorders and the new product launches by major market players, are expected to boost market growth. However, the slow turnaround time for autoimmune disease diagnostic test results and the high frequency of false positive results are expected to impede the market growth during the forecast period.

North America Autoimmune Disease Diagnostics Industry Segmentation

As per the report's scope, autoimmunity involves the loss of normal immune homeostasis as the organism produces an abnormal response to its tissue. Autoimmune diseases generally involve the presence of self-reactive T cells, autoantibodies, and inflammation. The diagnosis can be useful in managing patients suffering from autoimmune diseases and help provide a prognosis or indicate the severity of organ involvement or damage.

The North American autoimmune disease diagnostics market is segmented by disease type, diagnostic test, and geography. The market is segmented by disease type into systemic autoimmune disease and localized autoimmune disease. The systemic autoimmune diseases include rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and other diseases. The localized autoimmune diseases include inflammatory bowel disease, Type 1 diabetes, thyroid, and other localized autoimmune diseases. By diagnosis tests, the market is segmented into regular laboratory tests, inflammatory markers, immunologic assays, antibody tests, and other tests. By geography, the market is segmented into the United States, Canada, and Mexico. The report offers the value (in USD) for the above segments.